Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%
Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Active, not recruiting1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

active_not_recruiting133%
completed133%
not_yet_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingnot_applicable

Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT

NCT05931302
not_yet_recruitingnot_applicable

[68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).

NCT07313033
completedphase_2

68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer

NCT05160051

Clinical Trials (3)

Showing 3 of 3 trials
NCT05931302Not Applicable

Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT

Active Not Recruiting
NCT07313033Not Applicable

[68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).

Not Yet Recruiting
NCT05160051Phase 2

68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer

Completed

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3